Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: GlobeNewswire
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. Details of the presentations are as follows: IDDST 2024. Osaka, Japan. May 22-24, 2024. Title: Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary AngioedemaPresenter: Anne Lesage, Ph.D.Format: Oral PresentationDate, time: Wednesday, May 22, 10:55-11:20 a.m. JST (Tuesday, May 21, 9:55-10:20 p.m. EDT) EAC 2024. Palm Beach, Florida, U.S. May 30-June 2, 2024.
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris Announces Annual Meeting of ShareholdersGlobeNewswire
- Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses [Yahoo! Finance]Yahoo! Finance
- Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesGlobeNewswire
- Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Wedbush from $35.00 to $31.00. They now have an "outperform" rating on the stock.MarketBeat
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
PHVS
Earnings
- 5/8/24 - Beat
PHVS
Sec Filings
- 6/12/24 - Form 144
- 6/11/24 - Form 144
- 6/11/24 - Form 6-K
- PHVS's page on the SEC website